Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2007-12-25
2007-12-25
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S185100, C424S186100, C424S193100, C424S196110
Reexamination Certificate
active
10659324
ABSTRACT:
The present invention comprises novel and modified peptides capable of inducing an HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are based on conserved regions of HIV gag p24 proteins. Antigens in free- or carrier-bound form comprising at least one of the said peptides, vaccine compositions containing at least one of the antigens, immunoassay kits and a method of detecting antibodies induced by HIV or HIV specific peptides using such antigens, are described.
REFERENCES:
patent: 3711016 (1987-04-01), None
patent: 0 230 222 (1987-07-01), None
patent: 0 270 114 (1987-12-01), None
patent: 0 307 149 (1989-03-01), None
patent: 2 188 639 (1987-10-01), None
patent: 0 356 007 (1990-02-01), None
patent: 91/13360 (1991-09-01), None
patent: 94/28871 (1994-12-01), None
patent: 95/11255 (1995-04-01), None
patent: 96/27013 (1996-09-01), None
patent: 98/40744 (1998-09-01), None
Riffkin et al. “A single amino-acid change between the antigenically different extracellular serine proteases V2 and B2 from Dichelobacter nodosus”, Gene, vol. 167 (1995), pp. 279-283.
Abaza et al. “Effects of amino acid substitutions outside and antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization”, Journal of Protein Chemistry, vol. 11, No. 5 (1992), pp. 433-444.
Cruse et al. Illustrated Dictionary of Immunology (Boca Raton, FL, CRC Press, Inc., 1995), p. 309. QR180.4.C78.
Paul, Fundamental Immunology, (Philadelphia & New York, Lippincott-Raven Publsihers, 1993), pp. 250 and 1311-1312. QR181.F84.
Cohen et al. “Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge”, Proceedings of the National Academy of Sciences of the United States of America, vol. 96, Issue 19(Sep. 14, 1999), pp. 10842 10847.
Fox “No winners against AIDS”, Bio/Technology, vol. 12 (Feb. 1994), p. 128.
Journal of Virology, vol. 73, No. 1, Jan. 1999, Kavita S. Lole et al., “Full-length Human Immunodeficiency Virus Type 1 Genomes from Subtype C-Infected Seroconverters in India, with Evidence of Intersubtype Recombination,” pp. 152-160.
Nature, vol. 354, Dec. 1991, Rodney E. Phillips, “Human Immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition,” pp. 453-459.
Human Retroviruses and Aids, Bette Korber et al., “Protein Alignment Summary Table (Gag),” II-A-1 to II-A-15, Dec. 1997.
Virology, vol. 2, Jun. 1994, Gabriel Zwart et al., “Antibody Resonses to HIV-1 Envelope and GAG Epitopes in HIV-1 Seroconverters with Rapid versus Slow Disease Progression,” pp. 285-293.
Proceedings of the National Academy of Sciences, vol. 91, No. 23, Nov. 8, 1994, Douglas F. Lake et al. “Autoantibodies to the α/β T-cell receptors in human immunodeficiency virus infection: Dysregulation and mimicry,” pp. 10849-10853.
Clinical and Experimental Immunology, vol. 87, No. 1, Jan. 1992, S.J.D. Bell et al., “Definition of an immunodominant T cell epitope contained in the envelope gp41 sequence of HIV-1,” pp. 37-45.
Nature, vol. 369, No. 6479, Jun. 2, 1994, Paul Klenerman, et al., “Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants,” pp. 403-407.
Nature, vol. 369, No. 6479, Jun. 2, 1994, Antonio Bertoletti et al., “Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells,” p. 407.
Immunology and Cell Biology, vol. 72, issue 6, Dec. 1994, Gordon Ada, “Twenty years into the saga of MHC-restriction,” pp. 447-454.
Journal of Immunology, vol. 147, No. 5, Set. 1, 1991, R.P. Johnson et al., “HIV-1 gag-Specific Cytotoxic T Lymphocytes Recognize Multiple Highly Conserved Epitopes” “Fine Specificity of the gag-Specific Response Defined by Using Unstimulated Peripheral Blood Mononuclear Cells and Cloned Effector Cells,” pp. 1512-1521.
Science, vol. 278, Nov. 21, 1997, Eric S. Rosenberg et al. “Vigorous HIV-1-Specific CD4+T Cell Responses Associated with Control of Viremia,” pp. 1447-1450.
Novelty Search Report issued by the Hungarian Patent Office on Feb. 27, 2002 in counterpart Hungarian application (i.e., P0200265).
Bionor A/S
Campell Bruce R.
Fitzpatrick ,Cella, Harper & Scinto
Humphrey Louise
LandOfFree
Method of producing an HIV-1 immune response does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of producing an HIV-1 immune response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of producing an HIV-1 immune response will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3845685